<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129340">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01753076</url>
  </required_header>
  <id_info>
    <org_study_id>112264</org_study_id>
    <nct_id>NCT01753076</nct_id>
  </id_info>
  <brief_title>Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis</brief_title>
  <official_title>Study NOG112264, a Phase II Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Belgium: Agence Fédérale des Médicaments et des Produits de la Santé</authority>
    <authority>The Netherlands: De Centrale Commissie Mensgebonden Onderzoek</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>United States: Institutional Review Board</authority>
    <authority>Italy: Comitato Etico per la Sperimentazione, Azienda Ospedaliera Universitaria Integrata di Verona</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <authority>South Korea: Food and Drug Administration</authority>
    <authority>Australia: Therapeutic Goods Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 48-week, randomised, multi-centre, double-blind, placebo-controlled, parallel
      group investigation of the efficacy and safety of intravenous (IV) ozanezumab (GSK1223249)
      compared to placebo in subjects with Amyotrophic Lateral Sclerosis (ALS). Following a
      screening period of up to four weeks, eligible subjects will be randomised (1:1) to receive
      IV placebo or 15 milligram (mg)/ kilogram (kg) IV ozanezumab every 2 weeks for a period of
      48 weeks with a follow-up visit around 14 weeks after the last infusion. A total of
      approximately 294 eligible subjects will be randomised from approximately 37 centers
      worldwide. The primary objective is to assess the effect of ozanezumab on the physical
      function and survival of ALS subjects over a treatment period of 48 weeks. Function will be
      measured using the ALS Functional Rating Scale - Revised (ALSFRS-R). Secondary objectives
      include the evaluation of other clinical outcomes associated with ALS (respiratory function,
      muscle strength, progression free survival and overall survival) in support of the primary
      objective. Quality of life, safety, tolerability, immunogenicity and pharmacokinetics
      (ozanezumab and riluzole) will also be assessed.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To assess the effect of ozanezumab on the function and survival of ALS patients</measure>
    <time_frame>Over 48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The effect of ozanezumab on the function and survival of ALS patients will be measured by the joint rank scores for combined analysis of function and survival measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) over 48-weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in amyotrophic lateral sclerosis functional rating scale-revised (ALSFRS R)</measure>
    <time_frame>Week 48</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Slow Vital Capacity (SVC)</measure>
    <time_frame>Week 48</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Muscle Strength as measured by Hand Held Dynamometry (HDD)</measure>
    <time_frame>Week 48</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Clinical Global Impression - Improvement Scale (CGI-I) responders at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (at Week 48 and Week 60)</measure>
    <time_frame>Up to Week 48 and up to  Week 60</time_frame>
    <safety_issue>No</safety_issue>
    <description>Defined as time from randomisation to death or censored at Week 48 / Week 60 whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>Up to Week 48</time_frame>
    <safety_issue>No</safety_issue>
    <description>Defined as time from randomisation to progression or death or censored at Week 48 whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 48 in EuroQol-Short form (EQ 5D-L)</measure>
    <time_frame>Week 48</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 48 in amyotrophic lateral sclerosis assessment questionnaire-40 (ALSAQ 40)</measure>
    <time_frame>Week 48</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events (AEs)</measure>
    <time_frame>Throughout the study (screening upto follow-up)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of subjects with incidence of AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in vital signs (systolic blood pressure, diastolic blood pressure and heart rate)  and weight</measure>
    <time_frame>up to Week 60</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in routine laboratory tests</measure>
    <time_frame>up to Week 60</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in electrocardiogram (ECG) parameters</measure>
    <time_frame>up to Week 60</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters at steady state</measure>
    <time_frame>W0, W2 (only part A), W4, W8, W12, W24, W36, W44, W48, W60</time_frame>
    <safety_issue>No</safety_issue>
    <description>Estimates of individual ozanezumab PK parameters, including AUC(0-tau)ss, Cavgss, will be listed and summarized</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of riluzole</measure>
    <time_frame>W0, W2 (only part A), W4, W8, W12, W24, W36, W44, W48, W60</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the immunogenicity of IV ozanezumab</measure>
    <time_frame>W0, W12, W24, W36, W48 and Follow-up (W&gt;=60)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Incidence of anti-ozanezumab antibodies and relationship to trough concentration in serum will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of decline over 48 weeks in amyotrophic lateral sclerosis functional rating scale-revised (ALSFRS R) total score</measure>
    <time_frame>Week 48</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">294</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Ozanezumab IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered by IV route. Treatment period - 48 Weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline by IV route. Treatment period  - 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ozanezumab</intervention_name>
    <description>Ozanezumab injection solution</description>
    <arm_group_label>Ozanezumab IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline (0.9% sodium chloride) infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with diagnosis of familial or sporadic ALS

          -  Onset of muscle weakness no more than 30 months before screening visit.

          -  Slow Vital Capacity (SVC) of at least 65% predicted for gender, age, ethnicity and
             height at Screening.

          -  If on riluzole, the dose must have been stable for at least 28 days prior to Baseline
             visit.

          -  Age 18 - 80 years inclusive.

          -  Female subjects may participate if they are of non-child-bearing potential or if they
             are of child-bearing potential they must agree to use the approved contraceptive
             methods

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt;=2x upper limit
             of normal (ULN); alkaline phosphatase and bilirubin &lt;=1.5xULN.

          -  QTc (both QTcB and QTcF) &lt;450 milliseconds (msec) or &lt;480 msec for subjects with
             Bundle Branch Block at Screening and Baseline (average from triplicate ECGs).

        Exclusion Criteria:

          -  Patients with other neuromuscular disorders (including a history of polio) which in
             the opinion of the investigator could have contributed to the muscular atrophy or
             weakness caused by ALS

          -  Patients with primary lateral sclerosis, monomelic ALS, ALS Parkinsonism dementia
             complex.

          -  Patients requiring non-invasive or mechanical ventilation (non-invasive ventilation
             for sleep apnoea is allowed subject to discussion with Medical Monitor)

          -  Patients on diaphragmatic pacing.

          -  Presence of any of the following clinical conditions: Drug abuse or alcoholism,
             uncontrolled hypertension, active major infectious disease, unstable psychiatric
             illness within 90 days of the Screening visit

          -  Subjects, who in the investigator's judgement, pose a significant suicide risk.  -
             Current or chronic history of liver disease, known hepatic or biliary abnormalities
             (with the exception of Gilbert's syndrome or asymptomatic gallstones), positive
             Hepatitis B surface antigen or Hepatitis C antibody test.

          -  Subjects who have participated in a clinical trial involving receipt of a
             biopharmaceutical product within 6 months prior to the first dosing day.

          -  Exposure to non-biological experimental agents 1 month or 5 half-lives prior to
             Baseline visit (whichever is longer).

          -  History of sensitivity to ozanezumab, or components thereof, or a history of other
             allergies that, in the opinion of the investigator, contraindicates participation in
             the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3M 1M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lille cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Limoges cedex</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montpellier cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nice cedex 3</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris cedex 13</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Wuerttemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bochum</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jena</city>
        <state>Thueringen</state>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Torino</city>
        <state>Piemonte</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Verona</city>
        <state>Veneto</state>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kanagawa</city>
        <zip>252-0380</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miyagi</city>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>560-8552</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>133-792</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Preston</city>
        <state>Lancashire</state>
        <zip>PR2 9HT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brighton</city>
        <zip>BN2 5BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Edgbaston, Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 27, 2014</lastchanged_date>
  <firstreceived_date>December 17, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amyotrophic lateral sclerosis</keyword>
  <keyword>efficacy</keyword>
  <keyword>ozanezumab</keyword>
  <keyword>safety</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
